Compounds > 1,3-dipropyl-8-cyclopentylxanthine

1,3-dipropyl-8-cyclopentylxanthine and cystic fibrosis transmembrane conductance regulator (505-511)

1,3-dipropyl-8-cyclopentylxanthine has been researched along with cystic fibrosis transmembrane conductance regulator (505-511) in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ahrens, RC; Aitken, ML; Hilliard, KA; Kelley, TJ; Konstan, MW; Launspach, J; McCarty, NA; Milgram, LJ; Regelmann, WE; Standaert, TA; Teresi, M; Tuthill, C; Weatherly, MR	1

Trials

1 trial(s) available for 1,3-dipropyl-8-cyclopentylxanthine and cystic fibrosis transmembrane conductance regulator (505-511)

Article	Year
A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. Pediatric pulmonology, 2002, Volume: 33, Issue:2 Topics: Adolescent; Adult; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Dose-Response Relationship, Drug; Female; Humans; Male; Membrane Potentials; Mutation, Missense; Nasal Mucosa; Peptide Fragments; Purinergic P1 Receptor Antagonists; Regression Analysis; Research Design; Sweat; Treatment Outcome; Xanthines	2002

Article

Year

A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis.

Pediatric pulmonology, 2002, Volume: 33, Issue:2

Topics: Adolescent; Adult; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Dose-Response Relationship, Drug; Female; Humans; Male; Membrane Potentials; Mutation, Missense; Nasal Mucosa; Peptide Fragments; Purinergic P1 Receptor Antagonists; Regression Analysis; Research Design; Sweat; Treatment Outcome; Xanthines

2002